Which patients with mCRPC on ADT + advanced anti-AR do you treat with bisphosphonates or denosumab?   

Did you change your practice given the SRE results in the control arm of EORTC 1333 at ASCO 2021?

When using bisphosphonates or denosumab, what dosing and frequency do you use?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Loyola University Chicago Stritch School of Medicine
@Andrew J. Armstrong What are your preferred agent...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
There is improvement in SRE with denosumab vs. bis...
Medical Oncologist at Duke University School of Medicine
This is a good question. For mHSPC patients, I do ...
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice